Oxymetazoline is under clinical development by Levation Pharma and currently in Phase II for Ptosis. According to GlobalData, Phase II drugs for Ptosis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Oxymetazoline LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Oxymetazoline overview

Oxymetazoline (LEV-102) is under development for the treatment of acquired blepharoptosis (ptosis). It acts by targeting alpha-adrenergic receptors and is administered through ophthalmic route.

Levation Pharma overview

Levation Pharma (Levation) is developing of a topical oxymetazoline product or gel with acquired blepharoptosis designed to be used for cosmetic eye lifts. Levation is headquartered in Tel Aviv, Israel.

For a complete picture of Oxymetazoline’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.